A L Mindikoglu1, J P Raufman, S L Seliger, C D Howell, L S Magder. 1. Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. amindiko@medicine.umaryland.edu
Abstract
BACKGROUND: Since implementation of the Model for End-stage Liver Disease (MELD), the number of simultaneous liver-kidney transplantations (SLKT) has increased in the United States. However, predictors and survival benefit of SLKT compared to liver transplantation alone (LTA) are not well defined. METHODS: Organ Procurement and Transplantation Network data of patients with end-stage liver disease (ESLD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) who had not been on dialysis while on the waiting list and underwent liver transplantation between 2002 and 2008 were analyzed. To identify predictors of undergoing SLKT versus LTA, multiple logistic regression analysis was performed. Cox proportional hazards regression analysis was used to assess the association between SLKT and post-liver transplant patient and graft survival. RESULTS: The study cohort comprised 5443 patients; 262 (5%) underwent SLKT and 5181 (95%) underwent LTA. Adjusting for potential confounders, patients who underwent SLKT were 34% less likely to die after liver transplantation than those who underwent LTA (hazard ratio [HR] = 0.66, P = .012) and 33% less likely to have liver graft failure than those who underwent LTA (HR = 0.67, P = .010). Among those who underwent SLKT, 1-, 3-, and 5-year kidney graft survival probabilities were 88%, 80%, and 77%, respectively. Black race and diabetes were associated with a higher likelihood of SLKT versus LTA; female sex, a higher eGFR, and higher MELD score reduced the likelihood of SLKT. CONCLUSIONS: Among those with ESLD and kidney dysfunction not on dialysis, post-liver transplant patient and liver graft survivals of patients who underwent SLKT were superior to those of patients who underwent LTA. Whether this reflects differences in the two groups that could not be adjusted in survival models or a specific effect of kidney dysfunction cannot be established.
BACKGROUND: Since implementation of the Model for End-stage Liver Disease (MELD), the number of simultaneous liver-kidney transplantations (SLKT) has increased in the United States. However, predictors and survival benefit of SLKT compared to liver transplantation alone (LTA) are not well defined. METHODS: Organ Procurement and Transplantation Network data of patients with end-stage liver disease (ESLD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) who had not been on dialysis while on the waiting list and underwent liver transplantation between 2002 and 2008 were analyzed. To identify predictors of undergoing SLKT versus LTA, multiple logistic regression analysis was performed. Cox proportional hazards regression analysis was used to assess the association between SLKT and post-liver transplant patient and graft survival. RESULTS: The study cohort comprised 5443 patients; 262 (5%) underwent SLKT and 5181 (95%) underwent LTA. Adjusting for potential confounders, patients who underwent SLKT were 34% less likely to die after liver transplantation than those who underwent LTA (hazard ratio [HR] = 0.66, P = .012) and 33% less likely to have liver graft failure than those who underwent LTA (HR = 0.67, P = .010). Among those who underwent SLKT, 1-, 3-, and 5-year kidney graft survival probabilities were 88%, 80%, and 77%, respectively. Black race and diabetes were associated with a higher likelihood of SLKT versus LTA; female sex, a higher eGFR, and higher MELD score reduced the likelihood of SLKT. CONCLUSIONS: Among those with ESLD and kidney dysfunction not on dialysis, post-liver transplant patient and liver graft survivals of patients who underwent SLKT were superior to those of patients who underwent LTA. Whether this reflects differences in the two groups that could not be adjusted in survival models or a specific effect of kidney dysfunction cannot be established.
Authors: E Cholongitas; L Marelli; A Kerry; D W Goodier; D Nair; M Thomas; D Patch; A K Burroughs Journal: Am J Transplant Date: 2007-01-11 Impact factor: 8.086
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Paul A Skluzacek; Robert G Szewc; Charles R Nolan; Daniel J Riley; Shuko Lee; Pablo E Pergola Journal: Am J Kidney Dis Date: 2003-12 Impact factor: 8.860
Authors: Jayme E Locke; Daniel S Warren; Andrew L Singer; Dorry L Segev; Christopher E Simpkins; Warren R Maley; Robert A Montgomery; Gabriel Danovitch; Andrew M Cameron Journal: Transplantation Date: 2008-04-15 Impact factor: 4.939
Authors: Ranjeeta Bahirwani; Kimberly A Forde; Yifei Mu; Fred Lin; Peter Reese; David Goldberg; Peter Abt; K Rajender Reddy; Matthew Levine Journal: Clin Transplant Date: 2014-01-02 Impact factor: 2.863
Authors: Islam M Korayem; Vatche G Agopian; Keri E Lunsford; Hans A Gritsch; Jeffrey L Veale; Gerald S Lipshutz; Hasan Yersiz; Coney L Serrone; Fady M Kaldas; Douglas G Farmer; Suphamai Bunnapradist; Gabriel M Danovitch; Ronald W Busuttil; Ali Zarrinpar Journal: Clin Transplant Date: 2019-05-07 Impact factor: 2.863
Authors: Su-Hsin Chang; Mei Wang; Xiaoyan Liu; Tarek Alhamad; Krista L Lentine; Mark A Schnitzler; Graham A Colditz; Yikyung Park; William C Chapman Journal: Transplantation Date: 2019-08 Impact factor: 4.939
Authors: Xun Luo; Allan B Massie; Christine E Haugen; Rashikh Choudhury; Jessica M Ruck; Ashton A Shaffer; Sheng Zhou; Dorry L Segev; Jacqueline M Garonzik-Wang Journal: Transplantation Date: 2018-04 Impact factor: 4.939
Authors: Bekir Tanriover; Malcolm P MacConmara; Justin Parekh; Cristina Arce; Song Zhang; Ang Gao; Arjmand Mufti; Swee-Ling Levea; Burhaneddin Sandikci; Mehmet U S Ayvaci; Venketash K Ariyamuthu; Christine Hwang; Sumit Mohan; Mutlu Mete; Miguel A Vazquez; Jorge A Marrero Journal: Kidney Int Rep Date: 2016-08-03